Biomarker panel flags aggressiveness of ovarian cancer cases; New research predicts fast growth for biomarker business;

> A team at Cedars-Sinai's Samuel Oschin Comprehensive Cancer Institute has built up a 10-gene biomarker panel for ovarian cancer that can be used to determine the aggressiveness of an individual's disease. Release

> A new report from Allied Market Research concludes that the biomarker business for diagnostics will hit $30.6 billion by 2020. The business is growing at an annual rate of 16%. Release

> Biothera says it's been building up its knowledge of a biomarker that could be used to help identify patients most likely to respond to their late-stage immunotherapy Imprime PGG, which is being studied for colorectal cancer. Release

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.